Roivant’s Matt Gline on the hub-and-spoke biotech model and lessons learned from Axovant
Bio Pharma Dive
JANUARY 23, 2023
This year could stay turbulent for the biotech sector as investors look for what the Roivant CEO described in an interview with BioPharma Dive as “safe harbors in a storm.
Let's personalize your content